AbCellera Revenue and Competitors
Estimated Revenue & Valuation
- AbCellera's estimated annual revenue is currently $443.8M per year.
- AbCellera received $10.0M in venture funding in October 2018.
- AbCellera's estimated revenue per employee is $659,406
- AbCellera's total funding is $371.2M.
- AbCellera's current valuation is $2.8B. (January 2022)
Employee Data
- AbCellera has 673 Employees.
- AbCellera grew their employee count by 11% last year.
AbCellera's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Site Head and VP, Complex Membrane Protein Technologies | Reveal Email/Phone |
3 | Co-founder and VP, Discovery | Reveal Email/Phone |
4 | Head Risk, Assurance & Advisory | Reveal Email/Phone |
5 | VP Business Development | Reveal Email/Phone |
6 | VP, Communications | Reveal Email/Phone |
7 | VP, Translational Research | Reveal Email/Phone |
8 | VP, Alliance Management Partnering | Reveal Email/Phone |
9 | SVP, CMC Development and GMP Manufacturing | Reveal Email/Phone |
10 | VP, Research Partnerships | Reveal Email/Phone |
AbCellera Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $84M | 82 | -61% | $272.6M | $652.5M |
#2 | $124.8M | 910 | 1% | $567.2M | $2.2B |
What Is AbCellera?
AbCellera is a privately held company located in Vancouver, Canada, that is a world-leading innovator in antibody discovery for therapeutics, and immune profiling for vaccine research. AbCellera works in partnerships with researchers from academia, non-profit organizations, and industry to enable and accelerate the development of new antibody therapies and new vaccines. Our single-cell platform integrates end-to-end capabilities for therapeutic antibody discovery through a combination of technologies including proprietary immunizations, microfluidics, high-throughput imaging, genomics, computation, and laboratory automation. Ultra-deep screening of single B cells allows us unprecedented access to natural immune responses, and enables rapid isolation of large and diverse panels of high-quality lead antibodies from any species, including humans. The combination of speed, screening depth, and greater specificity translates to successful discovery against difficult targets such as membrane proteins, GPCRs and ion channels.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$371.2M
Total Funding
673
Number of Employees
$443.8M
Revenue (est)
11%
Employee Growth %
$2.8B
Valuation
N/A
Accelerator
AbCellera News
AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Consensus Rating of Buy from Analysts. Posted by admin on Apr 12th, 2022.
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop...
AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move...
Acquisition expands AbCellera's existing capabilities to unlock difficult-to-drug transmembrane proteins for antibody discovery programs VANCOUVER, British Columbia & BOSTON, September 13, 2021 - AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generat ...
AbCellera, Canada’s most valuable biotech company, has broken ground on a new 380,000-square foot tech hub in Vancouver that is set to serve as the company’s new headquarters. The hub comes in ahead of the Vancouver company’s plans to add “hundreds” of employees to its current 250-person workfo ...
Other Companies in Vancouver
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $215.7M | 682 | 9% | N/A |
#2 | $35M | 684 | N/A | N/A |
#3 | $210.1M | 686 | 3% | N/A |
#4 | $88.4M | 693 | -17% | N/A |
#5 | $75M | 720 | 8% | N/A |
AbCellera Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2018-10-01 | $10.0M | A | DCVC Bio | Article |